ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,292Medicare Part D Prescriptions Filled, Including Refills

Rank: 65 out of 1269

$610K Total Retail Price of All Prescriptions

Rank: 86 out of 1269

410 Patients Receiving at Least One Drug in Part D
88%Patients 65 Years and Older
34% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Maryland
Lower avg

Schedule Two
Controlled Substances

10% of this provider’s 410 patients filled at least one prescription for a schedule two drug, compared to an average of 7%.

Schedule Three
Controlled Substances

6% of this provider’s 410 patients filled at least one prescription for a schedule three drug, compared to an average of 5%.

Risky Drugs to Seniors

1% of this provider’s 8,944 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

25% of this provider’s prescriptions were for brand-name drugs, compared to an average of 26%.

Prescription Price

$59 was the average price of a prescription from this provider, compared to $69 among peers.

Prescriptions per Patient

25 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Maryland
LEVOTHYROXINE SODIUM 469 465 1 4
FUROSEMIDE 446 420 2 5
SIMVASTATIN 392 352 3 3
LISINOPRIL 317 299 4 1
METOPROLOL SUCCINATE 282 260 5 13
AMLODIPINE BESYLATE 251 231 6 2
OMEPRAZOLE 193 156 7 8
LOSARTAN POTASSIUM 183 168 8 15
ATENOLOL 180 150 9 14
HYDROCHLOROTHIAZIDE 178 167 10 10
WARFARIN SODIUM 175 173 11 12
CITALOPRAM HBR 168 156 12 21
PREDNISONE 147 133 13 45
GABAPENTIN 140 116 14 17
METFORMIN HCL 136 108 15 9
METOPROLOL TARTRATE 126 111 16 6
ESCITALOPRAM OXALATE 121 101 17 58
MIRTAZAPINE 114 114 18 24
POTASSIUM CHLORIDE 104 86 19 26
PRAVASTATIN SODIUM 104 81 19 11
KLOR-CON M20 103 97 21 60
PANTOPRAZOLE SODIUM 95 76 22 18
ZOLPIDEM TARTRATE 95 83 22 19
NAMENDA 94 94 24 38
RANITIDINE HCL 92 73 25 27
TRAMADOL HCL 87 82 26 16
ADVAIR DISKUS 85 74 27 46
CRESTOR 84 72 28 25
HYDROCODONE-ACETAMINOPHEN 81 64 S3 29 20
FAMOTIDINE 80 71 30 85
ATORVASTATIN CALCIUM 76 67 31 7
CLOPIDOGREL 76 76 31 32
CYMBALTA 73 33 33 70
RAMIPRIL 73 70 33 96
CELEBREX 72 72 35 95
VENLAFAXINE HCL ER 70 55 36 140
SPIRIVA 69 68 37 64
SERTRALINE HCL 68 59 38 23
BENAZEPRIL HCL 64 64 39 156
CARVEDILOL 64 63 39 29
ALENDRONATE SODIUM 64 64 39 28
PAROXETINE HCL 64 64 39 71
AZITHROMYCIN 62 53 43 42
OXYCODONE-ACETAMINOPHEN 58 42 S2 44 44
JANTOVEN 55 55 45 52
LOVASTATIN 55 55 45 30
DOXAZOSIN MESYLATE 54 54 47 117
SULFAMETHOXAZOLE-TRIMETHOPRIM 53 46 48 84
DONEPEZIL HCL 53 53 48 22
DIVALPROEX SODIUM 52 33 50 54
OXYCONTIN 50 13 S2 51 116
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.